Simcere Files to Test Innovative Cancer Drug from US Biopharma
publication date: Mar 11, 2011
Simcere Pharma has filed an Investigational New Drug (IND) application with the SFDA to start a Phase I trial of a novel monoclonal antibody intended to treat various forms of solid-tumor cancer. The mAb, known as APX003, was discovered by Apexigen of California. Simcere collaborated with Apexigen on the IND-enabling studies and owns China rights to the molecule. To advance its own development program, Apexigen has licensed China rights for three of its molecules to three China companies and collaborated with them on pre-clinical development. More details....
Stock Symbol: (NYSE: SCR) Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.